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Conclusions Copanlisib was well tolerated in Japanese 
patients with advanced or refractory solid tumors, and the 
maximum tolerated dose was determined to be 0.8 mg/kg. 
Copanlisib demonstrated near dose-proportional pharma-
cokinetics and preliminary disease control, warranting fur-
ther investigation.
Clinical trial registration number NCT01404390.
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Introduction
The phosphatidylinositol 3-kinases (PI3Ks) are a family 
of lipid kinases with key roles in intracellular signaling 
cascades regulating many cellular processes [1]. How-
ever, PI3K-mediated activation of downstream effectors, 
including the serine/threonine kinase AKT and mamma-
lian target of rapamycin (mTOR), is key to promoting cell 
survival proliferation and differentiation and is aberrantly 
activated in a variety of human cancers [2, 3]. Activation 
of the PI3K/AKT pathway is one of the major mechanisms 
by which tumors escape negative regulation of prolifera-
tion and become resistant to chemotherapy, targeted agents, 
and radiation. PI3K inhibitors therefore provide a promis-
ing therapeutic strategy not only in PI3K pathway-driven 
tumors but also in combination with other chemotherapy 
agents [4].
Copanlisib (BAY 80-6946; Bayer Pharma AG, Berlin, 
Germany) is a potent pan-class I PI3K inhibitor that is 
highly selective for PI3K compared with mTOR, and with 
preferential activity against the p110α and p110δ isoforms 
of PI3K, compared with the p110β and p110γ isoforms [5]. 
Copanlisib has demonstrated promising antitumor activity 
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in preclinical tumor models with either PIK3CA mutation 
or PTEN deletion and/or overexpression of human epi-
dermal growth factor receptor 2 [6]. Preclinical data from 
models of non-small-cell lung cancer, colorectal cancer, 
and breast cancer have provided support for the investiga-
tion of the combination of PI3K- and mitogen-activated 
protein kinase inhibition [7–9]. Copanlisib is therefore a 
potential candidate for use in PI3K-driven tumors either 
alone or in combination with other agents.
In a first-in-human Phase I study conducted in the USA, 
copanlisib was generally safe and well tolerated, and the 
maximum tolerated dose (MTD) was determined to be 
0.8 mg/kg [10]. Copanlisib also showed promising antitu-
mor pharmacodynamic activity and preliminary clinical 
benefit in patients with a range of advanced solid tumors 
and in patients with non-Hodgkin’s lymphoma. This 
study evaluated the safety, tolerability, pharmacokinetics 
(PK), and efficacy of copanlisib in Japanese patients with 
advanced or refractory solid tumors.
Materials and methods
This study was conducted in accordance with the Declara-
tion of Helsinki. Documented approval from the appropri-
ate ethics committees and institutional review boards was 
obtained for all participating centers before study initiation, 
where required.
Study design
This uncontrolled, open-label, non-randomized, single-
center, Phase I study evaluated the safety, tolerability, and 
PK as a primary objective, and the efficacy as a secondary 
objective, of copanlisib in Japanese patients with advanced 
or refractory solid tumors. The study comprised two 
cohorts, one at a dose of copanlisib 0.4 mg/kg (cohort 1) 
and one at copanlisib 0.8 mg/kg (cohort 2), the MTD deter-
mined in a previous first-in-human study [10]; this study 
aimed to evaluate whether the previously defined MTD in 
a non-Japanese study could be applied to Japanese patients 
with solid tumors.
Patients received a single intravenous infusion of copan-
lisib over 1 h on days 1, 8, and 15 of a 28-day cycle, with 
1 week of rest. On cycle 1, day 1, patients were required 
to fast for at least 8 h before and for 2 h following the end 
of the copanlisib infusion, at which point food intake was 
permitted. Dosing on days 8 and 15 was permitted within 
a window of ±1 day if necessary, and dosing was consid-
ered missed if delayed by more than 1 day. Dose delays 
of up to 2 weeks were permitted for day 1 of cycle 2 or 
later, although for days 8 and 15 of cycle 2 and subsequent 
cycles, dosing within a window of ±3 days was permitted, 
except for in cycle 3, where dosing was to be administered 
within ±1 day of days 8 and 15.
Patients were enrolled into cohort 1 and were evalu-
ated for the occurrence of a dose-limiting toxicity (DLT) as 
defined by the National Cancer Institute Common Termi-
nology Criteria for Adverse Events version 4.03. If no DLT 
was observed in cycle 1, or if treatment was continued with 
dose reduction, and if patients were deemed to derive treat-
ment benefit per the investigators’ judgment, then patients 
were either enrolled into cohort 2 (copanlisib 0.8 mg/kg) 
with additional informed consent or able to discontinue 
study treatment. Completion of cycle 1 in cohort 1 consti-
tuted study completion. During cycle 2, patients received 
copanlisib 0.8 mg/kg and treatment was continued until 
disease progression or unacceptable toxicity.
Three patients were to be initially enrolled into cohort 1; 
if no DLT was observed, cohort 2 was to be initiated. If a 
DLT was observed in one of the three patients in cohort 1, an 
additional three patients were to be enrolled into cohort 1. 
If a DLT was observed in one of the six patients, cohort 2 
was to be initiated. Enrollment to cohort 1 was discontin-
ued if a DLT was observed in two or more patients, and 
subsequent enrollment was to be determined by the sponsor 
following consultation with the investigator. Six patients 
were to be treated in cohort 2, with dose acceptability con-
firmed following consultation with the investigator.
Protocol-defined DLTs included non-hematologic 
adverse events of grade ≥3. Hyperglycemia defined as a 
DLT was to be determined based on serum glucose values. 
Hematologic DLTs were defined as grade 4 neutropenia for 
≥3 days, an absolute neutrophil count <1000 with fever 
≥38.5 °C, and grade 4 thrombocytopenia. Patients with 
non-hematologic DLTs were to discontinue study treat-
ment. However, patients with grade 3 hyperglycemia based 
on a fast of ≥8 h who responded to insulin, or hyperglyce-
mia that became grade ≤2 within 24 h of insulin admin-
istration, and patients dosed at 0.8 mg/kg and who expe-
rienced non-hematologic DLTs other than hyperglycemia, 
but showed subjective or objective clinical benefit, could 
continue the study at the reduced dose of 0.4 mg/kg.
Dose reduction from 0.8 to 0.4 mg/kg was permitted: 
following a non-glucose and non-hematologic DLT in the 
previous cycle, when dosing on days 8 and 15 of the pre-
vious cycle was missed because of hematologic toxicity 
or hematologic DLT; and when two or more cases of glu-
cose-related DLT occurred in the previous cycle despite a 
change in insulin regimen. Patients who did not tolerate the 
0.4 mg/kg dose were to be withdrawn from the study.
Patients were hospitalized for safety observations dur-
ing cycle 1, after which patients could be discharged at the 
investigators’ discretion. In cohort 1, the second patient was 
not enrolled until completion of the safety assessment fol-
lowing the first copanlisib infusion in the first patient.
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Patients
Japanese patients at least 20 years old with advanced or 
refractory, histologically or cytologically confirmed, non-
hematologic, malignant solid tumors unamenable to stand-
ard therapy (without past or current central nervous system 
involvement) were eligible for inclusion in this study. Addi-
tional inclusion criteria were: at least one measurable lesion 
or evaluable disease according to Response Evaluation Cri-
teria in Solid Tumors (RECIST) version 1.1; Eastern Coop-
erative Oncology Group performance status (ECOG PS) 0 or 
1; and life expectancy >12 weeks. Patients were excluded if 
they met the following criteria: investigational drug therapy, 
anticancer chemotherapy, immunotherapy, or radiotherapy to 
target lesions within 4 weeks before study entry; type 1 or 2 
diabetes mellitus or a fasting blood glucose level >125 mg/dL 
at screening and/or glycated hemoglobin ≥6.5%; past or 
current history of cardiac disease or congestive heart fail-
ure (New York Heart Association Class II); active coronary 
artery disease; myocardial infarction within 6 months of 
study entry; or new onset of angina <3 months before study 
entry. Additional exclusion criteria included: active and 
serious infections of grade >2 as defined by National Can-
cer Institute Common Terminology Criteria for Adverse 
Events version 4.03; seizure disorders requiring medication; 
uncontrolled hypertension (defined as systolic blood pres-
sure >150 mmHg or diastolic pressure >90 mmHg, despite 
optimal management); known HIV infection or chronic 
hepatitis B or C virus infection; inadequate bone marrow, 
liver, and renal functions (as assessed by laboratory val-
ues of hemoglobin <9.0 g/dL, absolute neutrophil count 
<1500/mm3, platelet count <100,000/mm3, total bilirubin 
>2 × upper limit of normal [ULN], alanine aminotransferase 
and aspartate aminotransferase >2.5 × ULN [or >5 × ULN 
for patients with liver involvement in their cancer], serum 
creatinine >1.5 × ULN, creatinine clearance ≥50 mL/min, 
prothrombin time/prothrombin time international normalized 
ratio ≥1.5 × ULN); renal dialysis; bleeding diathesis; ongo-
ing substance abuse; pregnant or breastfeeding; and the use 
of strong inhibitors of CYP3A4.
Assessments
Screening comprised: provision of written, informed con-
sent; demographics; baseline characteristics; concomitant 
medications; safety assessments (adverse events [defined 
as any new finding not present in the patient’s medical his-
tory, or a worsening of a prior medical history finding], vital 
signs, laboratory tests, physical examination, 12-lead elec-
trocardiogram, multigated acquisition scan, or echocardio-
gram); tumor measurements by computed tomography or 
magnetic resonance imaging; disease assessment as defined 
by RECIST version 1.1; ophthalmologic examination; chest 
computed tomography; and ECOG PS assessment. The fol-
lowing assessments were also performed on cycle 1, day 1: 
safety; ECOG PS assessment; concomitant medications; 
blood samples for PK analysis; serum samples for glucose 
analysis; serum insulin; urinalysis; serum ketones; and post-
dose echocardiogram. Safety assessments, blood pressure 
measurements, blood sampling for PK analysis, and urinal-
ysis were also performed on days 8 and 15 of cycle 1.
Blood sampling for PK analysis of serum was performed 
on cycle 1, day 1 at 0, 0.5, 1, 1.5, 2, 3, 5, 8, 11, 25, 49, 
and 168 h following the start of copanlisib infusion. Addi-
tional PK samples were collected at either 72, 96, or 120 h 
following the start of infusion. PK samples were also col-
lected on cycle 1, day 15 at 0, 0.5, 1, 1.5, 2, 3, 5, 8, 11, and 
25 h following the start of infusion and on cycle 3, day 15 
at 0, 0.5, 1, 1.5, 2, 3, 5, and 8 h following the start of infu-
sion. Blood pressure monitoring was performed every 
5 min before dosing on cycle 1, day 1 until the observa-
tion of two consecutive measurements <150 mmHg (sys-
tolic) and <90 mmHg (diastolic). Blood pressure was also 
measured before the collection of each blood PK sample, 
up to 49 h following the start of copanlisib infusion. Serum 
samples for glucose analysis were collected immediately 
before the first infusion and in parallel with PK sampling 
through to 49 h post-dose. Glucose samples taken at 25 h 
post-dose were to be fasting, where possible and if deemed 
safe. Capillary blood glucose testing was to be performed 
for hyperglycemia management as determined appropri-
ate by the investigator; hyperglycemia was defined as cap-
illary blood glucose >200 mg/dL and was to be treated 
with short-acting insulin. Tumor measurement and disease 
assessment according to RECIST version 1.1 were con-
ducted every two cycles by the investigator.
Statistical analysis
This study was primarily a descriptive safety and toler-
ability trial, and no formal sample-size estimation was 
performed. Summary statistics were used for demograph-
ics, baseline characteristics, and PK parameters. Frequency 
tables were used for categorical variables.
Results
Baseline demographics and characteristics
Ten patients were enrolled into the study and all received 
treatment. Three patients received copanlisib 0.4 mg/kg and 
seven patients received copanlisib 0.8 mg/kg. The major-
ity of patients were female (60.0%), with a median age of 
59.5 years (range 51.0–65.0) (Table 1). The majority of 
patients had ECOG PS 0 at baseline (80.0%), and colon 
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cancer was the most common tumor type (40.0%). Median 
time since initial diagnosis was 109.9 weeks for patients in 
cohort 1 and 190.4 weeks for patients in cohort 2 (Table 1). 
All patients had received prior systemic anticancer therapy 
(Table 1).
Copanlisib treatment
Overall, the median duration of treatment was 6.2 weeks 
(range 1.1–21.1): 6.3 weeks (range 6.1–10.9) in cohort 1 
and 6.1 weeks (range 1.1–21.1) in cohort 2. The median 
number of treatment cycles, including interruptions, delays, 
and drug holidays, was two overall (range 1–6): two 
cycles (range 2–3) in cohort 1 and two cycles (range 1–6) 
in cohort 2. The median number of copanlisib infusions 
received was six (range 2–15) across both cohorts, with a 
range of 6–8 infusions in cohort 1 and a range of 2–15 infu-
sions in cohort 2.
No patients experienced DLTs in cohort 1. A non-hema-
tologic DLT (grade 3 diarrhea, which was recorded as pos-
sibly related to the study drug) was recorded in one patient 
receiving copanlisib 0.8 mg/kg in cohort 2. The patient 
with the DLT was withdrawn from the study and recovered, 
and no further DLTs were reported. The MTD in Japa-
nese patients was therefore determined to be copanlisib 
0.8 mg/kg. One patient in cohort 2 did not receive the third 
dose of copanlisib in cycle 1 as planned because of disease 
progression, and discontinued the study, prompting enroll-
ment of one additional patient into this cohort.
Safety
All ten patients experienced at least one treatment- 
emergent adverse event (TEAE), and all experienced 
at least one adverse event assessed by the investigator 
as drug-related. The most commonly reported TEAEs 
of all grades irrespective of causality were hypergly-
cemia (80.0%), hypertension (70.0%), and constipa-
tion (50.0%) (Table 2). TEAEs of grade 3 as worst 
grade were reported in five patients overall (50.0%), 
with two considered drug-related (20.0%) (Table 2). 
Grade 3 or 4 TEAEs were reported in one patient from 
cohort 1 (33.3%) and five patients from cohort 2 (71.4%) 
(Table 3). Grade 3 hyperglycemia, diarrhea, and lympho-
cytopenia were considered to be possibly drug-related 
(Table 3). One grade 4 TEAE was recorded and was not con-
sidered to be drug-related: increased aspartate aminotrans-
ferase in one patient with liver metastases in cohort 2. 
Serious adverse events were reported in three patients in 
cohort 2: grade 2 presyncope and grade 3 diarrhea in one 
Table 1  Demographics and baseline characteristics
Cohort 1, 0.4 mg/kg (n = 3) Cohort 2, 0.8 mg/kg (n = 7) Total (N = 10)
Female, n (%) 3 (100) 3 (42.9) 6 (60.0)
Asian race, n (%) 3 (100) 7 (100) 10 (100)
Median age, years (range) 59.0 (57.0–64.0) 60.0 (51.0–65.0) 59.5 (51.0–65.0)
Eastern Cooperative Oncology Group performance status, n (%)
0 3 (100) 5 (71.4) 8 (80.0)
1 0 2 (28.6) 2 (20.0)
Cancer classification, n (%)
Non-small-cell lung 0 2 (28.6) 2 (20.0)
Bladder 0 1 (14.3) 1 (10.0)
Kidney 1 (33.3) 0 1 (10.0)
Colon 2 (66.7) 2 (28.6) 4 (40.0)
Pancreatic adenocarcinoma 0 1 (14.3) 1 (10.0)
Gastrointestinal stromal tumor 0 1 (14.3) 1 (10.0)
Median time since initial diagnosis, weeks (range) 109.9 (98.9–153.1) 190.4 (27.0–548.3) 131.5 (27.0–548.3)
Prior systemic anticancer therapy, n (%) 3 (100) 7 (100) 10 (100)
Number of prior systemic anticancer therapies, n (%)
1 1 (33.3) 1 (14.3) 2 (20.0)
2 1 (33.3) 0 1 (10.0)
3 1 (33.3) 1 (14.3) 2 (20.0)
4 0 2 (28.6) 2 (20.0)
5 0 1 (14.3) 1 (10.0)
6 0 2 (28.6) 2 (20.0)
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patient (both events considered drug-related), grade 3 hepa-
tobiliary disorders (not considered drug-related) in one 
patient, and grade 3 stroke (not considered drug-related) in 
another. No grade 5 adverse events were reported, irrespec-
tive of causality.
All patients reported at least one hematologic and bio-
chemical toxicity event, the most frequent of which were 
increased creatinine and hyperglycemia (both in all ten 
patients), hypoalbuminemia and anemia (90.0% overall; 
two patients in cohort 1 and seven patients in cohort 2), and 
lymphocytopenia (90% overall; three patients in cohort 1 
and six in cohort 2).
Two adverse events leading to study discontinua-
tion were reported (20.0%), both occurring in cohort 2 
(Table 2). These were grade 3 diarrhea in one patient and 
grade 1 thrombocytopenia in another; both events were 
considered drug-related. Overall, no intra-cycle dose modi-
fication or dose modification for subsequent cycles was 
performed.
Eight patients withdrew from the study because of dis-
ease progression (three in cohort 1 and five in cohort 2): 
two patients discontinued in cycle 1, five in cycle 2, two in 
cycle 3, and one in cycle 5.
Pharmacokinetics
All patients were included in the single-dose PK 
assessment of copanlisib. Plasma geometric mean 
Table 2  Summary of adverse events
AE adverse event, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase
n (%) Cohort 1, 0.4 mg/kg (n = 3) Cohort 2, 0.8 mg/kg (n = 7) Total (N = 10)
Any AE 3 (100) 7 (100) 10 (100)
Grade 3 AE 1 (33.3) 4 (57.1) 5 (50.0)
Grade 4 AE 0 1 (14.3) 1 (10.0)
Any serious AE 0 3 (42.9) 3 (30.0)
AEs leading to dose modification 1 (33.3) 5 (71.4) 6 (60.0)
AEs leading to permanent discontinuation of study drug 0 2 (28.6) 2 (20.0)
Any drug-related AE 3 (100) 7 (100) 10 (100)
Grade 3 drug-related AE 0 2 (28.6) 2 (20.0)
Treatment-emergent AEs of all grades, irrespective of causality, occurring in ≥2 patients in total
Hyperglycemia 1 (33.3) 7 (100) 8 (80.0)
Hypertension 1 (33.3) 6 (85.7) 7 (70.0)
Constipation 3 (100) 2 (28.6) 5 (50.0)
Lymphocytopenia 0 4 (57.1) 4 (40.0)
Increased ALP 1 (33.3) 3 (42.9) 4 (40.0)
Neutropenia 1 (33.3) 3 (42.9) 4 (40.0)
Tumor pain 1 (33.3) 3 (42.9) 4 (40.0)
Leukopenia 1 (33.3) 3 (42.9) 4 (40.0)
Fever 2 (66.7) 2 (28.6) 4 (40.0)
Investigations, other 2 (66.7) 2 (28.6) 4 (40.0)
Anemia 0 3 (42.9) 3 (30.0)
Anorexia 0 3 (42.9) 3 (30.0)
Nausea 0 3 (42.9) 3 (30.0)
Acneiform rash 1 (33.3) 2 (28.6) 3 (30.0)
Increased ALT 1 (33.3) 2 (28.6) 3 (30.0)
Increased AST 0 2 (28.6) 2 (20.0)
Flu-like symptoms 0 2 (28.6) 2 (20.0)
Insomnia 0 2 (28.6) 2 (20.0)
Malaise 0 2 (28.6) 2 (20.0)
Oral mucositis 0 2 (28.6) 2 (20.0)
Pruritus 0 2 (28.6) 2 (20.0)
Cough 1 (33.3) 1 (14.3) 2 (20.0)
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concentrations of copanlisib following administration on 
cycle 1, day 1 are presented in Fig. 1. Maximum drug con-
centration (Cmax) and exposure (area under the curve from 
0 to 25 h after dosing [AUC(0–25)]) increased in a roughly 
dose-proportional manner between 0.4 and 0.8 mg/kg. 
Inter-patient variability in copanlisib Cmax and AUC(0–25) 
on cycle 1, day 1 was low to moderate, with coefficient of 
variation values of 14.5–32.5% for Cmax and 19.3–32.0% 
for AUC(0–25). No accumulation was observed after mul-
tiple dosing at either dose level, 0.4 mg/kg (Table 4) or 
0.8 mg/kg (Table 5). The geometric mean terminal half-
life was approximately 32 h (Table 4) to 36 h (Table 5) 
after single dosing.
Treatment efficacy
All ten patients who received treatment were evaluable 
for efficacy. Of the ten patients, none experienced a com-
plete or partial response. Four patients had stable disease 
(40.0%; one patient in cohort 1 and three in cohort 2) as 
best response, and six had progressive disease (60.0%; two 
patients in cohort 1 and four in cohort 2) as best response 
(Table 6). The disease control rate was therefore 40.0% 
(33.3% for cohort 1 and 42.9% for cohort 2).
Overall, median time to progression was 52 days (95% 
confidence interval [CI] 21–82): 52 days (95% CI 50–77) 
for cohort 1 and 53 days (95% CI 21–not estimated) for 
Table 3  Grade 3 or 4 treatment-emergent adverse events and investigator assessment of relationship to study drug
ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase
n (%) Grade Cohort 1, 0.4 mg/kg (n = 3) Cohort 2, 0.8 mg/kg (n = 7) Relationship to study drug
Increased AST 4 0 1 (14.3) Not likely to be related
Increased ALP 3 1 (33.3) 1 (14.3) Not likely to be related
Increased ALT 3 0 2 (28.6) Not likely to be related
Anemia 3 0 2 (28.6) Not likely to be related
Hyperglycemia 3 0 1 (14.3) Possibly related
Diarrhea 3 0 1 (14.3) Possibly related
Hepatobiliary disorder 3 0 1 (14.3) Not likely to be related
Insomnia 3 0 1 (14.3) Not likely to be related
Lymphocytopenia 3 0 1 (14.3) Possibly related


















241.5 2 3 4 6 48 72
Cohort 2: copanlisib 0.8 mg/kg
Cohort 1: copanlisib 0.4 mg/kg
Fig. 1  Geometric mean (geometric standard deviation) of copanlisib concentrations in plasma on cycle 1, day 1. Error bars represent geometric 
standard deviation
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Table 4  Geometric mean 
(% coefficient of variation) 
single- and multiple-dose 
pharmacokinetic parameters  
of copanlisib 0.4 mg/kg in 
cycles 1 and 3
AUC area under the curve, AUC(0–8) area under the curve from 0 to 8 h after dosing, AUC(0–25) area under 
the curve from 0 to 25 h after dosing, AUC(0–25)/D AUC(0–25) divided by dose (mg), AUC(0–25)norm AUC(0–25) 
divided by dose per kg body weight, Cmax maximum drug concentration, Cmax,norm maximum drug concen-
tration divided by dose per kg body weight, N/C not calculated, tmax time to maximum drug concentration, 
t1/2 half-life associated with terminal slope
a Median [range]
Cycle 1, day 1 (n = 3) Cycle 1, day 15 (n = 3) Cycle 3, day 15 (n = 1)
AUC, µg·h/L 1400 (31.1) N/C N/C
AUC(0–8), µg·h/L 483 (38.5) 292 (15.3) 289
AUC(0–25), µg·h/L 789 (32.0) 536 (13.6) N/C
AUC(0–25)/D, µg·h/L 0.0382 (36.6) 0.0264 (9.22) N/C
AUC(0–25)norm, kg·h/L 1.99 (29.3) 1.37 (11.9) N/C
Cmax, µg/L 215 (34.7) 133 (23.1) 109
Cmax/D, 1/L 0.0104 (30.0) 0.0065 (17.3) 0.0055
Cmax,norm, kg/L 0.543 (31.7) 0.341 (21.0) 0.282
tmax
a, h 0.50 [0.48–0.58] 0.50 [0.47–0.50] 1.02
t1/2, h 32.2 (76.8) N/C N/C
Table 5  Geometric mean 
(% coefficient of variation) 
single- and multiple-dose 
pharmacokinetic parameters  
of copanlisib 0.8 mg/kg in 
cycles 1 and 3
AUC area under the curve, AUC(0–8) area under the curve from 0 to 8 h after dosing, AUC(0–25) area under 
the curve from 0 to 25 h after dosing, AUC(0–25)/D AUC(0–25) divided by dose (mg), AUC(0–25)norm AUC(0–25) 
divided by dose per kg body weight, Cmax maximum drug concentration, Cmax,norm maximum drug concen-
tration divided by dose per kg body weight, N/C not calculated, tmax time to maximum drug concentration, 
t1/2 half-life associated with terminal slope
a Median [range]
Cycle 1, day 1 (n = 7) Cycle 1, day 15 (n = 6) Cycle 3, day 15 (n = 1)
AUC, µg·h/L 2350 (14.3) N/C N/C
AUC(0–8), µg·h/L 812 (17.8) 768 (20.4) 570
AUC(0–25), µg·h/L 1280 (19.3) 1290 (10.1) N/C
AUC(0–25)/D, µg·h/L 0.0274 (14.7) 0.0294 (10.8) N/C
AUC(0–25)norm, kg·h/L 1.61 (18.6) 1.62 (11.1) N/C
Cmax, µg/L 447 (14.5) 410 (37.0) 395
Cmax/D, 1/L 0.0096 (20.2) 0.0094 (31.3) 0.0084
Cmax,norm, kg/L 0.565 (13.9) 0.517 (38.0) 0.499
tmax
a, h 0.53 [0.50-1.08] 0.75 [0.48-1.05] 1.02
t1/2, h 35.6 (73.1) N/C N/C
Table 6  Best overall disease 
response with respect to 
Response Evaluation Criteria in 
Solid Tumors
a By proven measurement
n (%) Cohort 1, 0.4 mg/kg 
(n = 3)
Cohort 2, 0.8 mg/kg 
(n = 7)
Total (n = 10)
Complete response 0 0 0
Partial response 0 0 0
Stable disease 1 (33.3) 3 (42.9) 4 (40.0)
Progressive diseasea 2 (66.7) 4 (57.1) 6 (60.0)
Overall response rate (complete 
response + partial response)
0 0 0
Overall disease control rate 
(complete response + partial 
response + stable disease)
1 (33.3) 3 (42.9) 4 (40.0)
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cohort 2. In cohort 2, one patient with gastrointestinal stro-
mal tumor had continued stable disease until the end of 
cycle 5 but discontinued treatment because of drug-related 
thrombocytopenia. Another patient in cohort 2 with stable 
disease discontinued treatment because of grade 3 diarrhea. 
Time to progression for these patients was censored at 176 
and 50 days, respectively. Another two patients with sta-
ble disease as best response had a time to progression of 
77 days (one patient in cohort 1) and 82 days (one patient 
in cohort 2). Overall, the rates of progression-free survival 
were 0.80 (95% CI 0.41–0.95) after 1 month, 0.35 (95% 
CI 0.08–0.64) after 2 months, and 0.12 (95% CI 0.01–0.40) 
after 3 months.
Discussion
This Phase I study evaluated the safety, tolerability, PK, 
and efficacy of the pan-PI3K inhibitor copanlisib in Japa-
nese patients with advanced or refractory solid tumors. 
Copanlisib was administered as a 1-h intravenous infusion 
once weekly for 3 weeks on days 1, 8, and 15 of a 28-day 
cycle.
The baseline demographics and disease characteristics 
of patients in this study were generally similar to those in 
the previously reported first-in-human study [10], except 
that patients in the current study were of Asian ethnicity 
and the current study did not include patients with hema-
tologic malignancies. The starting dose used here (copan-
lisib 0.4 mg/kg once weekly) was determined as half of 
the MTD defined in the first-in-human study (copanlisib 
0.8 mg/kg once weekly). Toxicities were expected to be 
manageable at the 0.4 mg/kg dose level with the use of 
short-acting insulin permitted to manage hyperglycemia, as 
reported in the first-in-human study [10]. The study design 
also ensured safety as patients were hospitalized for the 
duration of the first treatment cycle.
Copanlisib was well tolerated at the 0.4 mg/kg dose 
level, prompting enrollment at the 0.8 mg/kg dose level. 
Only one non-hematologic DLT was reported at the 
0.8 mg/kg dose level, prompting enrollment of one further 
patient into cohort 2 to confirm safety at this dose level, 
and no further DLTs were observed; the MTD in Japanese 
patients was therefore determined to be 0.8 mg/kg once 
weekly and generally consistent with the preceding first-
in-human study in non-Japanese patients [10]. Hypergly-
cemia and hypertension were the most commonly reported 
TEAEs, consistent with the first-in-human study [10]. 
Hyperglycemia is a known class effect of agents target-
ing the PI3K/AKT/mTOR signaling pathway [11] and was 
expected based on previous reports of other PI3K inhibitors 
[11–17] and the first-in-human study of copanlisib [10]. 
The hyperglycemia observed following copanlisib infusion 
is likely caused by inhibition of insulin signaling [18] and 
systemic insulin resistance [19], as previously reported in 
preclinical models of other PI3K/AKT pathway inhibitors. 
The mechanism for hypertension in this study is unclear 
and may arise from copanlisib-mediated inhibition of PI3K 
at the endothelial level leading to vasoconstriction [20], 
or through insulin-dependent vasoconstriction [21] as an 
effect of the post-infusion hyperglycemia, or both. How-
ever, the clinical significance of the increases in blood pres-
sure following copanlisib infusion remains unclear. Hyper-
glycemia and hypertension events were all grade 1 or 2, 
except for one case of grade 3 hyperglycemia. These events 
were generally transient and manageable and did not lead 
to discontinuation in any patient. In the larger Phase I first-
in-human study [10], hyperglycemia and hypertension were 
shown to be transient in nature, peaking at 5–8 or 1–2 h, 
respectively, after the start of infusion and then returning 
to normal values. The incidence of all-grade hypertension 
may have been higher here compared with the Patnaik et al. 
study (70 vs. 30%, respectively), but there were no reports 
of grade 3 hypertension here, compared with 19% grade 3 
hypertension in the Patnaik et al. study [10]. In the current 
study, two adverse events resulted in discontinuation and 
were attributed as drug-related, one of which (grade 3 diar-
rhea) resolved following discontinuation and one (grade 1 
thrombocytopenia) was unresolved. There were no cases of 
colitis, as has been reported for other orally administered 
PI3K inhibitors [12, 15]. No deaths on study were reported.
Gastrointestinal toxicity was relatively infrequent and 
mild in nature. Five patients had constipation (four grade 1), 
three had nausea (two grade 1), and one had grade 3 diar-
rhea. Two patients had grade ≥3 elevated aminotransferase 
levels, and this incidence may have been higher than seen 
in the first-in-human study, where <10% of patients had 
grade ≥3 elevated aminotransferase levels [10]. The over-
all incidence and severity of gastrointestinal toxicity seen 
with copanlisib in the current study and in the first-in-
human study are notably less than those reported for other 
orally administered PI3K inhibitors [12, 13, 15, 22, 23] and 
may be related to the route of administration and first-pass 
metabolism seen with orally administered drugs [10].
The PK exposures of copanlisib increased in near 
dose-proportional manner at 0.4 mg/kg and at the MTD, 
0.8 mg/kg, consistent with dose escalation in the first-in-
human study of copanlisib [10], with no accumulation and 
low to moderate inter-patient variability. The long plasma 
half-life of approximately 32–36 h suggests wide tissue 
distribution, supportive of once-weekly dosing, consist-
ent with the first-in-human study [10]. Overall, copanlisib 
PK parameters appeared consistent between Japanese and 
non-Japanese patients; however, the sample sizes used in 
this study were small, and variability was observed in PK 
parameters, so these data should be interpreted with some 
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caution. Recent analyses have indicated that an intermittent 
dosing schedule of 60 mg weekly on days 1, 8, and 15 of 
a 28-day cycle was likely to achieve a similar risk/benefit 
ratio as 0.8 mg/kg weight-based dosing [24], and the fixed-
dose schedule is under evaluation in ongoing studies.
Efficacy was a secondary objective in this small study, 
and no complete or partial responses were observed. In 
the larger first-in-human study, there were three objective 
responses (one complete response and two partial responses; 
objective response rate of 12%) among 25 patients in a 
solid-tumor expansion cohort treated at the MTD [10]. The 
disease control rate (complete response, partial response, or 
stable disease) in Japanese patients was 40%, similar to that 
reported for patients in the advanced solid-tumor expansion 
cohort in the first-in-human study (44%) [10]. Copanlisib 
also showed promising antitumor activity in a small number 
of patients with non-Hodgkin’s lymphoma in the first-in-
human study (seven out of nine patients) [10]. The prelimi-
nary efficacy data here remain inconclusive because of the 
exploratory nature of this analysis and the small number of 
patients evaluated in this study.
Overall, copanlisib was safe and well tolerated in Japa-
nese patients with advanced or refractory solid tumors, 
administered on days 1, 8, and 15 of a 28-day treatment 
cycle. The most common adverse events were hypergly-
cemia and hypertension, both of which were transient in 
nature and did not result in discontinuation of treatment. 
Gastrointestinal toxicity was generally infrequent. The 
MTD of copanlisib in Japanese patients was defined as 
0.8 mg/kg, and copanlisib PK data support a once-weekly 
dosing schedule. In this small study, copanlisib showed 
preliminary disease control, and these data support fur-
ther investigation of the safety and efficacy of copanlisib 
in Japanese patients with solid tumors and other advanced 
malignancies. A Phase Ib study into the safety of copanlisib 
in Japanese patients with relapsed, indolent B-cell non-
Hodgkin’s lymphoma is ongoing (NCT02342665), in addi-
tion to a wider program of studies into copanlisib safety, 
pharmacodynamics, PK, and efficacy in a range of patient 
populations and cancer types.
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